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Emerging infectious diseases cause a disproportionate
burden in developing countries, hindering economic and
political advancement. Because of global interdependence,
modern transportation, trade, and changing social and
cultural patterns, emerging or reemerging infections are also
threats to the United States (1). Therefore, the United States
has a vital and direct stake in the health of people around the
world, both out of humanitarian concern and enlightened
self-interest.
In the battle against infectious diseases, drugs, vaccines,
and pesticides are important weapons. Given the lack of
substantial markets for such products in developing
countries, public/private partnerships are essential to the
development of new ways to prevent and treat infectious
diseases in those populations that are poor and where the
burden of disease lies, largely in the developing world.
Kinds of Partnerships
Our understanding and control of emerging infections
can be advanced by several types of public/private
partnerships, such as those that support research, develop
drugs and vaccines, or advance policy development.
The role of philanthropical investments in partnerships
that support medical research is also an important
consideration. Strong investments in public health agencies,
both in facilities and programs, will enable public/private
partnerships to reach their full potential.1
Partnership To Support Research: Sequencing the
Malaria Genome
Sequencing the genomes of microorganisms, those that
either afflict millions of persons primarily in poorer parts of
the world or those that afflict persons in both the developing
and developed worlds in much smaller numbers, needs
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champions among public or philanthropic funders of
biomedical research because corporations will generally not be
interested in research on such organisms.
Sequence information can be essential to identifying
therapeutic approaches to diseases such as malaria. In
response to the rising global incidence of malaria, the
Burroughs Wellcome Fund (BWF) has joined with the
Wellcome Trust in the United Kingdom, the U.S. Department
of Defense, and the National Institute of Allergy and
Infectious Diseases (NIAID) to support the Malaria Genome
Project, an international effort to sequence the genetic code of
Plasmodium falciparum, the major causative agent of
malaria. This partnership has supported not only the
sequencing of the parasite’s 14 chromosomes but also the
development of databases and new tools for studying the
expression of the newly identified genes. The sequencing is
being carried out at the Sanger Center, at The Institute for
Genomic Research (TIGR) (with colleagues from the
Department of Defense) and at Stanford University. Data from
this project already have provided new insights into the
parasite’s biology and have helped advance vaccine research
(2). The malaria research community will participate in a
“jamboree,” similar to that held by scientists working on
Drosophila, at the end of 2001 to finish the sequencing of the
malaria genome.
The experience of funding this large-scale project has been
even more rewarding than BWF had anticipated. Along with the
new scientific insight it has provided, the Malaria Genome
Project has grown into a model consortium that comprises a
collaborative and interactive group able to work with scientists
locally and globally. Funders and scientists have developed a
strong relationship that allows “just in time” acquisition of
resources and an agile, responsive approach to planning.  In
addition, flexibility in the project’s funding (because different
organizations can support different aspects) has allowed the
consortium to take advantage of new technologies and
techniques. For example, the Burroughs Wellcome Fund was able
to provide seed dollars to convene the scientific community to
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discuss needs, select the strain to be sequenced and provide
funding for pilot work. The National Institute of Allergy and
Infectious Diseases and the Wellcome Trust provided funds for
sequencing while the Department of Defense provided expertise
and tool development.
Partnership for Drug Development:
Medicines for Malaria Venture
The Medicines for Malaria Venture (MMV) is a new public/
private partnership developed under the umbrella of the World
Health Organization’s (WHO) Roll Back Malaria Program
(Ridley, pers. comm.). Like the Malaria Genome Project, the
driving force behind the creation of MMV is the disease burden of
malaria in the developing world. The lack of vaccines and
increasing problems of drug resistance to the available drugs
mean that new antimalarial drugs are urgently needed.
Under the leadership of Win Gutteridge (WHO/TDR), a
strategic planning group was assembled from persons
representing large pharmaceutical companies, development
agencies, foundations, and international health organiza-
tions. The planning group confirmed the urgent need for new
antimalarial drugs but also noted that the market could not
support the high cost and risk associated with pharmaceuti-
cal drug company research and development (R&D) (as much
as $500 million per drug candidate). Since expertise in
pharmaceutical R&D resides with industry, the planning
committee sought to combine public and private sector
resources and expertise to “lower the risk” of drug
development and encourage industry to make new drugs.
MMV is set up as a not-for-profit business with a mission of
fostering and financing the discovery and development of new,
affordable antimalarial drugs. The organization’s goal is to have
one new product granted regulatory approval every five years
and to make arrangements for the products’ commercialization.
With each project, appropriate intellectual property would be
owned by MMV with commercialization through out-licensing.
To carry out its mission, MMV created a “public venture
capital fund” to support R&D projects on a competitive basis.
MMV accesses knowledge, experience, gifts-in-kind, and, if
appropriate, money from the private sector. However, MMV
seeks most of its financial resources from the public and
philanthropic sector.
As of May 2000, MMV has been constituted as an
independent foundation in Switzerland, the board has been
appointed, a CEO selected, the business plan completed, and
a portfolio of R&D projects funded. Although $30 million per
year by 2004 is required to meet the business plan, $15
million was raised for 1999/2000. MMV has received support
from development agencies, foundations, industry, and
health agencies. The organization is now selecting a second
round of projects after a promising selection of three first-
round projects from 101 applications.
Besides public/private partnerships to develop new drugs,
some groups have programs to control infectious diseases in the
developing world using donations of existing drugs. Industry has
made substantial donations to programs against onchocerciasis,
lymphatic filariasis, drug-resistant malaria, trachoma, and
leprosy that involve donations of Mectizan, Albendazole,
Malarone, Zithromax, and Leprosy MDT, respectively. Sixty
percent of corporate contributions to philanthropy were product
donations (3). In all cases the contribution from the company has
gone far beyond the provision of the drug to supporting
development of systems that will ensure the efficient
distribution and effective use of donated drugs.
The incentive for this kind of project is altruism, which
has obvious limits in the competitive commercial environ-
ments. Ventures that provide both “push” and “pull”
interventions are more likely to be sustained. A company or
partnership underwriting the cost of research and
development is a push intervention. Creating a market for the
drugs or vaccines being developed is a pull intervention. MMV
uses both strategies, supporting drug development and
working through WHO’s Roll Back Malaria activity and other
partners to assure the existence of a market for the drugs.
Partnership for Policy Development: Institute of
Medicine Emerging Infections Activities
In May 1989, Rockefeller University, the National Institute
of Allergy and Infectious Diseases, and the Fogarty
International Center cosponsored a conference on emerging viral
agents. Although the conference focused on viruses, it spurred
interest in the emergence and resurgence of all classes of
infectious agents. Subsequently, the Institute of Medicine (IOM)
convened a panel and carried out a study under the leadership of
Joshua Lederberg and Robert Shope that resulted in the 1992
report Emerging Infections: Microbial Threats to Health in the
United States (4). Funding for this study was provided by the
Centers for Disease Control and Prevention (CDC), the Fogarty
International Center, Lederle-Praxis Laboratories, the Lucille
B. Markey Charitable Trust, the National Institute of Allergy
and Infectious Diseases, the Rockefeller Foundation, and the
U.S. Army Medical Research and Development Command.
From the beginning, the broad support from private and public
agencies provided the foundation for an ongoing partnership for
policy development.
The report called for increasing investments in the public
health infrastructure, especially in surveillance, research, and
training; in the development and deployment of vaccines and
antimicrobial drugs and the control of resistance; vector control;
and research on personal and community health practices
relevant to disease transmission. Perhaps the most effective
response to the report came CDC under the leadership of Walter
Dowdle, James Hughes, and Ruth Berkelman, who put together
a CDC plan for addressing the issues raised in the report (5). This
plan galvanized congressional attention, and with the advocacy
of groups like the American Society for Microbiology and others,
drew attention to the need for additional resources and
investments in treating and preventing emerging infections.
Subsequently, in partnership CDC and NIAID asked the IOM to
establish the Forum on Emerging Infections as a convening
ground for public and private agencies to address continuing
issues and problems related to emerging infections.  The
Burroughs Wellcome Fund also supports this activity in which
policy makers can address the problem of emerging infections.
Philanthropic Investments
What role can philanthropy play in public/private
partnerships to address emerging infections?  Foundations are
uniquely qualified to initiate thought and action, experiment
with new and untried ventures, dissent from prevailing
attitudes, and act quickly and flexibly (6). Several kinds of
foundations are common. Independent foundations, such as the
Bill and Melinda Gates Foundation, are usually established by
an individual. Company-sponsored foundations include the524 Emerging Infectious Diseases Vol. 7, No. 3 Supplement, June 2001
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Figure 1. Giving in 1999: contributions received by type of recipient
organization in the United States (8)
Figure 2. U.S. health research and development expenditures (9)
Merck Foundation. The American Cancer Society is an example
of an operating or special interest foundation. The Research
Triangle Community Foundation is a community foundation,
which usually raise and manage money from different donors
and direct the contributions locally.
Foundation type as much as size influences patterns of
giving and growth. In 1999 there were 47,000 foundations in
the United States, many of them small family foundations
with assets of about $1 million. In the United States,
foundations with assets of $50 million or more represent 2% of
foundations, yet control 71% of total assets (7). In 1999, total
giving in the United States amounted to $190.16 billion (8).
Most contributions, nearly $160 billion, came from
individual donations; foundations contribute nearly $20
billion, and corporations and their foundations more than
$11 billion (60% in the form of product donations). Health
care received only 9.4% of philanthropic donations
(Figure 1) (8). In contrast, in 1996 U.S. health research and
development expenditures were close to $38 billion, with
industry investing more than half of those dollars and the
foundation contributions amounting to only 4% of the total
(Figure 2) (9). A 1997 survey of private funders of
biomedical research in the United States showed that $1.3
billion was invested that year. Thus philanthropic support
of $1-2 billion (10) for medical research is small in
comparison with that from NIH (1999 budget $15.6 billion)
or that from industry ($22 billion).
The entry of the Bill and Melinda Gates Foundation in support
of international health R&D has had a stunning effect because of the
comparatively large amount of money it has committed to the
philanthropically undervalued area of international health.
Perhaps, other foundations could be recruited to support this area
during the anticipated transfer of wealth projected over the next
decade if the public health community makes a cogent case for the
need and value of such investment.
Philanthropic organizations can move quickly to fill a
gap, function as neutral conveners, model successful
approaches, develop information for policy debate, fund
politically unpopular areas of research, and take risks.
Drawbacks of philanthropic support include limited funds for
research, less willingness to support overhead or infrastruc-
ture, the desire to model programs and move on, and the
tendency to resist collaborative ventures. Thus, philanthropic
organizations can be catalysts for developing public/private
partnerships, but these groups do have limitations because
they cannot commit as much money to emerging infections
research as industry or government agencies.
Conclusions
The following lessons can be derived from these examples
of public/private partnership and an examination of
philanthropic capacity:
1. Philanthopic support, though important as risk capital in
the system, is modest in comparison to industrial and
government support for medical research.
2. The amount of wealth expected to be transferred during the
period 1990-2040 has been estimated to exceed $10 trillion
(11), thus providing opportunities to capture additional
dollars for medical/health research and international
health.
3. Industry is an essential partner but needs both “push”
and “pull” mechanisms to participate in drug and vaccine
development for diseases that largely affect poor people.
4. Public health and government agencies need long-term,
increased investments to advance knowledge, to develop
vaccines and drugs, and to control emerging infectious
diseases.
5. Owing to the complexity and global nature of the issues in
emerging infections, partnerships are more important
today than ever before.
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